Clinical Trial Update: Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of an anti-C5aR antibody in healthy subjects has completed, reporting safety and pharmacokinetics data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis
• Systemic Lupus Erythematosus

Drugs mentioned

• Anti-C5aR antibody

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Inflammation, Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED